Previous investigations, including those from our group, have shown that apoA-I overexpression alleviates hepatic steatosis, improves insulin resistance, enhances autophagy, and reduces oxidative stress in models of MASLD. Here, APOA1 is linked to metabolic dysfunction-associated steatotic liver disease.